Multiple sclerosis in the UK: service use, costs, quality of life and disability.
BACKGROUND
Multiple sclerosis (MS) is a chronic condition that affects quality of life (QOL), leads to disability and requires ongoing care inputs. Few studies have examined the impact of QOL, disability and demographic characteristics on treatment costs.


OBJECTIVE
To investigate the links between service use, costs, QOL and disability for people with MS.


METHODS
A cross-sectional study was conducted in people with MS who were members of the Multiple Sclerosis Society of Great Britain and Northern Ireland. A questionnaire, consisting of sociodemographic questions, the Client Service Receipt Inventory, EQ-5D and Guy's Neurological Disability Scale (GNDS), was sent to 4000 members of the Society. Service and lost employment costs were calculated. Regression models were developed to identify the participant characteristics that were associated with costs, QOL and disability. All costs are presented in year 2006-7 values.


RESULTS
Questionnaires were returned by 1942 members (48.9%). The mean (SD) EQ-5D QOL score was 0.41 (0.34), whilst the GNDS disability score was 20.8 (8.9). The mean (SD) service cost over the preceding 6 months was pound8397 ( pound10,404), and most of this (71.6%) was due to informal care. Only a small amount of cost (8.1%) was due to the use of disease-modifying drugs and drugs for spasticity. Lost employment costs amounted to a mean of pound4240. Higher costs were associated with higher levels of disability and lower levels of health-related QOL.


CONCLUSIONS
This study showed that MS participants had high levels of service use, and that QOL was low in comparison with other conditions. There were significant associations between costs, QOL and disability.
McCrone
Paul
P
Institute of Psychiatry, King's College London, London, UK. p.mccrone@iop.kcl.ac.uk
Heslin
Margaret
M
Knapp
Martin
M
Bull
Paul
P
Thompson
Alan
A
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017281:Cost of Illness; D003430:Cross-Sectional Studies; D004185:Disability Evaluation; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data; D006296:Health Services / Q000191:economics* / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000191:economics* / Q000453:epidemiology; D011788:Quality of Life; D012044:Regression Analysis; D011795:Surveys and Questionnaires; D006113:United Kingdom / Q000453:epidemiology
Pharmacoeconomics. 1998 May;13(5 Pt 2):607-22
17165327
Pharmacoeconomics. 1998 May;13(5 Pt 2):597-606
17165326
Health Econ. 2004 Sep;13(9):873-84
15362179
Mult Scler. 2006 Oct;12(5):605-12
17086907
Fam Pract. 2005 Jun;22(3):323-7
15824056
J Neurol Neurosurg Psychiatry. 2004 Jan;75(1):56-60
14707308
Eur J Health Econ. 2006 Sep;7 Suppl 2:S96-104
17310341
Psychol Med. 2004 Aug;34(6):991-9
15554570
Acta Neurol Scand. 1997 May;95(5):268-74
9188900
Psychiatr Serv. 2002 Jul;53(7):879-81
12096173
Health Econ. 2007 May;16(5):531-6
17001749
Neurology. 2001 Apr 10;56(7):934-7
11294932
J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):439-42
12640058
Health Technol Assess. 2002;6(10):1-73
12022938
Mult Scler. 1998 Oct;4(5):419-25
9839302
Neurology. 1983 Nov;33(11):1444-52
6685237
Health Technol Assess. 1998;2(4):iii-54
9580870
Clin Neurol Neurosurg. 2002 Jul;104(3):272-5
12127667
Qual Life Res. 2006 Mar;15(2):259-71
16468081
Mult Scler. 1999 Aug;5(4):223-33
10467380
Health Technol Assess. 2000;4(36):1-83
11134918
J Neurol Neurosurg Psychiatry. 2006 Aug;77(8):918-26
16690691